CD274 and hepatocellular carcinoma: Immune checkpoint inhibitors (ICIs), either in combination or as monotherapy, are now a mainstay of the treatment landscape for patients with hepatocellular carcinoma (HCC).1-6 Anti-PD-1/PD-L1 monotherapy leads to durable responses in a minor subset of patients with HCC, and in comparative studies, offers non-inferior overall survival (OS) when compared to sorafenib.